Page URL:

23andMe's 'designer baby' tool patent draws attention

7 October 2013
Appeared in BioNews 725

A US genetics company has been awarded a patent that relates to a DNA analysis service that predicts a baby's traits on the basis of its parents' genes.

The California-based firm, 23andMe, says its Family Traits Inheritance Calculator, the service to which the patent relates, offers an 'engaging way for you and your partner to see what kind of traits your child might inherit from you'. However, the language used in the patent application when it was submitted five years ago suggests that its use in fertility clinics when choosing sperm and egg donors was also considered at the time.

Entitled 'Gamete Donor Selection Based on Genetic Calculations', the patent reveals how people could use the method described to choose a gamete donor with genes that are deemed likely to produce certain characteristics in a baby.

Using genetic information from a gamete donor and recipient, along with the option of including the recipient's phenotype preferences, the model is able to identify a 'preferred donor' from a range of potential donors by the calculating the likelihood of traits occurring in a resulting child. The ability to specify a preference for both eye colour and height, as well as inherited diseases and also 'lifespan', through a 'user-selectable interface' is outlined in the patent.

Speaking to the BBC, Dr Marcy Darnovsky, executive director of the Center for Genetics and Society, described the project as 'ethically and socially treacherous'. She said: 'It would be highly irresponsible for 23andMe or anyone else to offer a product or service based on this patent [...] it amounts to shopping for designer donors in an effort to produce designer babies'.

23andMe was quick to clarify its intentions, saying that it no longer planned to use the technology for anything more than as a way for its customers to see what kind of traits their child could inherit using their own genetic information.

In a blog post, the company said: 'At the time 23andMe filed the patent, there was consideration that the technology could have potential applications for fertility clinics so language specific to the fertility treatment process was included in the patent'.

'But much has evolved in that time...the company never pursued the concepts discussed in the patent beyond our Family Traits Inheritance Calculator, nor do we have any plans to do so'.

The Family Traits Inheritance Calculator service currently offered by the company has been available since 2009. The company offers DNA analysis of samples collected by post for $99.

In 2012 the company was granted its first patent, relating to potential applications of a gene it found to be associated with Parkinson's disease. At the time, some customers reacted angrily at the prospect of the company profiting from their genetic information (reported in BioNews 659).

23andMe's 'build-a-baby' patent criticised
BBC News |  3 October 2013
A 23andMe Patent
23andMe Blog |  1 October 2013
Personal-genetics firm denies pursuit of designer babies in patent filing
Nature News Blog |  2 October 2013
United States Patent no. 8543339
Free Patents Online |  24 September 2013
US firm patents DNA-analysis tool for planning a baby
New Scientist |  3 October 2013
7 December 2015 - by Lone Hørlyck 
This documentary shows that assisted reproduction is a huge and real business. Unfortunately, it does so without asking the necessary critical and ethical questions that would make it genuinely worth watching...
8 December 2014 - by Arit Udoh 
US-based genetic testing company 23andMe has launched its controversial 'personal genome service' in the UK...
10 March 2014 - by Ari Haque 
As part of the British Library's TalkScience season, a panel of eminent speakers to discussed the role of patents in biomedicine...
12 December 2013 - by Dr Ruth Stirton 
23andMe and UK Biobank are both large genetic databases: big enough to engage in serious population genetic research. But 23andMe has not undergone any ethical approval processes - think what they could do if they sold their database...
9 December 2013 - by Ruth Saunders 
Genetic testing company 23andMe, which last week suspended the sale of its health-related genetic tests, is now facing a class action lawsuit in California over its marketing claims....
22 July 2013 - by Professor Stephen Wilkinson 
Why are potentially positive developments like mitochondrial replacement therapy and next-generation sequencing greeted with talk of 'designer babies', and is such language justified?
20 August 2012 - by Ruth Saunders 
23andMe, a US-based personal genomics company, has sought regulatory approval from the Food and Drug Administration for seven of its genetic tests....
9 July 2012 - by Dr Megan Allyse 
When US based, direct-to-consumer genetic testing company 23andMe announced last month that it had obtained a patent on a method for determining predisposition to Parkinson's disease, it highlighted, perhaps inadvertently, a growing area of unresolved tension between clinical, commercial and research interests....
6 June 2011 - by Rosemary Paxman 
Direct-to-consumer (DTC) genetic tests provide an inaccurate prediction of disease risk and offer little benefit to consumers, scientists claim...
23andMe's patent ( - 08/10/2013)
This is a very interesting story.  One thing to keep in mind is what 23andMe's patent actually claims.  Here is a link to a discussion of the patent that just issued:
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.